Rotavirus Vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society. March 2006;Declaración del Comité Consultivo de Inmunizaciones (CCI) de la Sociedad Chilena de Infectología respecto a vacuna anti-rotavirus. Marzo 2006

Revista Chilena de Infectologia

Volumn 23, Issue 2, 2006, Pages 124-127

  Muñoz M , Alma ^a   Abarca V , Katia ^a   Luchsinger F , Vivian ^a   Valenzuela B , M Teresa ^a   Jiménez De La J , Jorge ^a  

^a Sociedad Chilena de Infectología ^*  (Chile)

Author keywords

Infants; Intussusception; Rotavirus; Rotavirus vaccine

Indexed keywords

LIVE VACCINE; RIX4414 VACCINE; ROTAVIRUS VACCINE;

ADVISORY COMMITTEE; AGE; ANIMAL; CATTLE; CHILE; DRUG APPROVAL; GASTROENTERITIS; HUMAN; IMMUNOLOGY; INFANT; INTUSSUSCEPTION; MEDICAL SOCIETY; REVIEW; ROTAVIRUS INFECTION; VIROLOGY; VIRUS INFECTION;

ADVISORY COMMITTEES; AGE FACTORS; ANIMALS; CATTLE; CHILE; DRUG APPROVAL; GASTROENTERITIS; HUMANS; INFANT; INTUSSUSCEPTION; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SOCIETIES, MEDICAL; VACCINES, ATTENUATED;

EID: 33744476116     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Parashar U D, Hummelman E G, Bresee J S, Miller M A, Glass R I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9: 565-72.
2. Parashar U D, Bresee J S, Glass R I. The global burden of diarrhoeal disease in children. Bull World Health Org 2003; 81: 236.
3. Podewils L J, Mintz E D, Nataro J P, Parashar UD. Acute infectious diarrhoea among children in developing countries. Semin Pediatr Infect Dis 2004; 15: 155-68.
4. Kane E M, Turcios R M, Arvay M L, García S, Bresee J S, Glass R I. The epidemiology of rotavirus diarrhea in Latin America. Anticipating rotavirus vaccines. Rev Panam Salud Publica 2004; 16: 371-7.
5. O'Ryan M, Pérez Schael I, Mamani N, Peña A, Salinas B, Gonzalez G et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J 2001; 20: 685-93.
6. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15: 29-56.
7. Gentsch J R, Laird A R, Bielfelt B, Griffin D D, Banyai K, Ramachandran M et al. Serotype diversity and reassortment between human and animal rotavirus strains: Implications for rotavirus vaccine programs. J Infect Dis 2005; 192: S146-59.
8. Cunliffe N, Bresee J, Gentsch J, Glass R. The expanding diversity of rotaviruses. Lancet 2002; 359: 640-2.
9. Cunliffe N A, Dove W, Bunn J E, Ramadam M B, Nyangao J W, Riveron R L et al. Expanding global distribution of rotavirus serotype G9: Detection in Lybia, Kenya, and Cuba. Emerg Infect Dis 2001; 7:890-2.
10. Castello A A, Arvay M L, Glass R I, Gentsch J. Rotavirus strain surveillance in Latin America: a review of the last nine years. Pediatr Infect Dis J 2004; 23: S168-72.
11. Linhares A C, Bresee J S. Rotavirus vaccines and vaccination in Latin America. Rev Panam Salud Publica/Pan Am J Public Health 2000; 8: 305-31
12. Wood D. WHO Informal Consultative Group. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines. Mexico City, Mexico, 8-9 February 2005.Vaccine 2005; 23: 5478-8.
13. Soares-Weiser K, Goldberg E, Tamimi G, Pitan OC, Leibovici L. Rotavirus vaccine for preventing diarrhoea. The Cochrane Database of Systematic Reviews 2004, Issue 1.
14. Glass R I, Bresee J S, Parashar U D, Turcios R, Fischer T, Jiang B et al. Rotavirus vaccines: past, present, and future. Arch Pediatr 2005; 12: 844-7.
15. Bresee J S, Parashar U D, Widdowson M A, Gentsch J R, Steele A D, Glass R I. Update on rotavirus vaccines. Pediatr Infect Dis J 2005; 24: 947-52.
16. Glass R I, Bresee J S, Turcios R, Fischer T K, Parashar U D, Steele A D. Rotavirus vaccines: Targeting the developing world. J Infect Dis 2005; 192: S160-6.
17. O'Ryan M. Vacunas anti-rotavirus:Al fin una realidad. Rev Chil Infect 2005; 22: 345-54.
18. Rennels M B, Glass R I, Dennehy P H, Bernstein D I, Pichichero M E, Zito E T, et al Safety and efficacy of high dose rhesushuman reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics 1996; 97: 7-13.
19. Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, et al. Efficacy and safety of high dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131: 632-8.
20. Intussusception among recipients of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 1999; 48: 577-81.
21. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, and Kapikian A. More on RotaShield and intussusception: The role of age at the time of vaccination. J Infect Dis 2005; 192: S36-43.
22. Salinas B, Pérez Schael I, Lindares A C, Ruiz Palacios G M, Guerrero M L, Yarzabal J P et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24: 807-16.
23. De Vos B, Vesikari T, Lindares A C, Salinas B, Pérez Schael I, Ruiz-Palacios G M, et al. A Rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004; 23: S179-S182.
24. Linhares A C, Ruiz-Palacios G M, Guerrero M L, Salinas B, Pérez-Schael I, Clemens S A, et al. A short report on highlights of world-wide development of RIX4414: A Latin American experience. Vaccine. En prensa. (Disponible online en www.scinedirect.com).
25. Ruiz-Palacios GM, Pérez-Schael I, Velazquez F R, Abate H, Breuer T, Clemens S C et al. Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11-22.
26. Steele A D, Tumbo J M, Armah G E, Reynders J, Scholtz F, Bos P, et al. Concomitant administration of live attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. Poster presented at ESPID Annual Meeting, May 2005.
27. Rotavirus and Rotavirus vaccines. Proceedings of the Sixth International Rotavirus Symposium July 7-9, 2004. Mexico City. Session IV. Results with new rotavirus vaccines. (http://www.rotavirus.org/documents/ MexicoCityProceedings_000.pdf).
28. Heaton P M, Goveia M G, Miller J M, Offit P, Clark H F. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005; 192: S17-21.
29. Vesikari T, Matson D O, Dennehy P, Van Damme P, Santosham M, Rodríguez Z et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23-33.
30. CDC's Advisory Committee recommends new vaccine to prevent rotavirus. February 21, 2006. http://www.cdc.gov/nip/pr_rotavirus (accedido 26 de febrero, 2006).